Clinical Trials on Platelet Rich Plasma in Japan

Total 207 results

Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets

Healthy | Plasma Concentration of ASP1941

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
National Cerebral and Cardiovascular Center

Recruiting

REASSURE-NIRS Registry (REASSURENIRS)

Lipid-Rich Atherosclerosis of Coronary Artery

Japan
Sanofi
Daiichi Pharmaceuticals

Completed

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Platelet Aggregation Inhibitors | NSTEACS

Japan
Fresenius Kabi Japan

Completed

Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery

Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage

Japan
Kyoto University, Graduate School of Medicine

Active, not recruiting

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS (STOPDAPT-2 ACS)

Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention | Acute Myocardial Infarction | Platelet Aggregation Inhibitors

Japan
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
Ministry of Health, Labour and Welfare, Japan

Unknown

A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients

Heparin-Induced Thrombocytopenia

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Idiopathic Thrombocytopenic Purpura

Japan
Takeda

Completed

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

Multiple Myeloma

Japan
Takeda

Completed

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Relapsed/Refractory Multiple Myeloma

Japan
Alexion Pharmaceuticals

Completed

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Japan
Alexion Pharmaceuticals

Completed

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Takeda

Completed

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Relapsed and/or Refractory Multiple Myeloma

Japan
Celgene

Completed

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Multiple Myeloma

Japan
GlaxoSmithKline

Active, not recruiting

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Multiple Myeloma

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic | Idiopathic Thrombocytopenic Purpura

Japan
Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Terminated

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Novartis Pharmaceuticals

Terminated

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Neoplasms, Haematologic

Japan
Eisai Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia

Thrombocytopenia Associated With Chronic Liver Disease

Japan
Ministry of Health, Labour and Welfare, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

Heparin-Induced Thrombocytopenia

Japan
Cutera Inc.

Completed

A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin

Melasma | Lentigines

China, Japan
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Celgene

Completed

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Multiple Myeloma

Japan
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Lymphoma | Multiple Myeloma

Japan
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Pfizer

Active, not recruiting

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Japan
Takeda

Completed

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Japan
Celgene

Completed

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Myelodysplastic Syndromes | Multiple Myeloma

Japan
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome

Japan, Turkey
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Bristol-Myers Squibb
AbbVie

No longer available

Early Patient Access Treatment Use Protocol CA204-220

Multiple Myeloma

Japan
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
Kyowa Kirin Co., Ltd.

Completed

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan

3

Subscribe